Atom Investors’s AbbVie ABBV Stock Holding History

Atom Investors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15,389	Closed	-$2.08M	–	188
2021 Q4	$2.08M	Buy	+15,389	New	+$1.82M	0.35%	54
2020 Q3	–	Sell	-30,542	Closed	-$3M	–	497
2020 Q2	$3M	Buy	+30,542	New	+$2.69M	0.2%	100
2020 Q1	–	Sell	-84,293	Closed	-$7.46M	–	313
2019 Q4	$7.46M	Sell	84,293 -87,982	-51%	-$7.3M	0.61%	53
2019 Q3	$13M	Buy	+172,275	New	+$11.8M	0.89%	26

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Atom Investors's ABBV Position: Q1 2022 in Review

Atom Investors sold out of AbbVie (ABBV) in Q1 2022, closing a stake of 15,389 shares — an estimated $2.08M sold.

Atom Investors first reported a position in ABBV in Q3 2019 and held it in 4 quarters. The position peaked at $13M in Q3 2019. 3,052 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

Atom Investors reported no remaining AbbVie position as of Q1 2022 after selling out during the quarter.
Atom Investors sold 15,389 AbbVie shares in Q1 2022, an estimated $2.08M.
Atom Investors first reported a position in AbbVie in Q3 2019 and held it in 4 quarters.
Atom Investors's AbbVie position peaked at $13M in Q3 2019.
3,052 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on Atom Investors's 13F filing for Q1 2022, filed 16 May 2022.